Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.
Dig Dis Sci. 2011 Nov;56(11):3335-42. doi: 10.1007/s10620-011-1750-7. Epub 2011 May 22.
The current standard treatment for patients infected with hepatitis C virus (HCV) of genotype 2 is the combination of peginterferon (PEG-IFN) plus ribavirin (RBV) for 24 weeks.
We assessed the sustained virological response (SVR) rates in HCV genotype 2-infected Japanese patients in relation to the duration of treatment.
Between 2006 and 2009, among 147 patients with HCV genotype 2-infection in Chiba Prefecture, 138 consecutive patients were finally enrolled. Twenty-one, 97 and 20 patients were treated with PEG-IFN-alfa 2b plus RBV for 16, 24 and 48 weeks, respectively. Epidemiological data and treatment outcomes were retrospectively evaluated. HCV RNA was measured with COBAS AMPLICOR HCV Monitor Test v. 2.0.
The overall SVR rate was 82.6% (114 of 138): treatment-naïve patients, 86.4% (89 of 103); patients with history of previous treatment, 71.4% (25 of 35). Patients treated for 16, 24 and 48 weeks obtained SVR rates of 66.6% (14 of 21), 86.5% (84 of 97) and 80.0 (16 of 20), respectively.
The SVR rates of PEG-IFN-alfa 2b plus RBV in Japanese patients were similar to those in previous studies. Combination treatment for 24 weeks for some patients infected with HCV genotype 2 may be superior to that for 16 weeks. More precise patient selection will be needed to shorten the combination treatment.
目前，对于感染丙型肝炎病毒（HCV）基因型 2 的患者，聚乙二醇干扰素（PEG-IFN）联合利巴韦林（RBV）治疗 24 周是标准治疗方法。
我们评估了日本 HCV 基因型 2 感染患者的持续病毒学应答（SVR）率与治疗持续时间的关系。
在 2006 年至 2009 年间，在千叶县的 147 例 HCV 基因型 2 感染患者中，最终有 138 例连续患者入组。21、97 和 20 例患者分别接受 PEG-IFN-alfa 2b 联合 RBV 治疗 16、24 和 48 周。回顾性评估了流行病学数据和治疗结果。采用 COBAS AMPLICOR HCV Monitor Test v. 2.0 检测 HCV RNA。
总体 SVR 率为 82.6%（114/138）：初治患者为 86.4%（89/103）；有既往治疗史的患者为 71.4%（25/35）。治疗 16、24 和 48 周的患者 SVR 率分别为 66.6%（14/21）、86.5%（84/97）和 80.0%（16/20）。
日本患者 PEG-IFN-alfa 2b 联合 RBV 的 SVR 率与既往研究相似。对于某些感染 HCV 基因型 2 的患者，24 周的联合治疗可能优于 16 周的治疗。需要更精确的患者选择以缩短联合治疗。
